TICKERNERD
Menu
ACXPACXPHealthcare · Biotechnology

ACXP Stock Forecast: Acurx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.25
−3.85% on the day

The 3 Wall Street analysts covering Acurx Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +700.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.2M
Ticker Nerd rank
22 / 100
Median analyst target
$10
Analysts covering
3
Revenue$0.0
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$1.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−12.6%
YTD
−49.8%
1Y
−84.6%
From 52W high
−84.6%
From 52W low
0.0%
$1.25
$8.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Acurx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Volatility
58
Quality
48
Growth
44
Accruals
38
Revisions
33
Issuance
26
Momentum
12
Value
10

Size (94): Smaller than most of the companies we track.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00Jan 26Apr 26Jul 26Oct 26ACXPHigh $31Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $10High $31

The green dot is the last close — the median target sits +700.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026HC Wainwright & Co.ReiteratesBuy$31
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy$31
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025HC Wainwright & Co.AssumesBuy$8.00
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
19 Mar 2024HC Wainwright & Co.MaintainsBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
15 Dec 2023HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—
13 Sept 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.MaintainsBuy—
15 May 2023HC Wainwright & Co.ReiteratesBuy—
11 Apr 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Acurx Pharmaceuticals, Inc. returned −84.6% against +16.2% for the S&P 500, dividends included.

ACXP vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ACXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Acurx Pharmaceuticals, Inc. (ACXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
0.5×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−128.1%

Higher than 11% of US stocks

Return on assets
−55.9%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Acurx Pharmaceuticals, Inc. (ACXP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acurx Pharmaceuticals, Inc. has a market value of $7.2M and an enterprise value of −$3.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$7.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.2M.

  • Shares outstanding: 4.3M.

  • Trailing P/E: −0.2×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Acurx Pharmaceuticals, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ACXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACXPAcurx Pharmaceuticals, Inc.$7.2M
22
APREAprea Therapeutics, Inc.$6.9M
45
BOLTBolt Biotherapeutics, Inc.$7.0M
78
AIMAIM ImmunoTech, Inc.$7.0M
19
ENVBEnveric Biosciences, Inc.$6.8M
21
NRSNNeurosense Therapeutics Ltd.$6.8M
3
LEXXLexaria Bioscience Corp.$6.7M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Acurx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACXP news & analysis

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

PRNewsWire · 29 Sept 2026positive

Acurx Pharmaceuticals announced that the first patient has been enrolled in PATHFINDER, a Phase 2 clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection. Results from the trial, along with the planned ASPIRE Phase 3 study in acute CDI, may inform a future active-controlled Phase 3 registration trial in rCDI.

Why it matters — This marks progress in advancing ibezapolstat's clinical development toward a potential single-agent treatment for recurrent C. difficile infection, which could shift how such infections are managed.

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs.

PRNewsWire · 14 Sept 2026positive

Acurx announced the presentation of a scientific poster at ICSD demonstrating superior in vitro kill kinetics of ibezapolstat. The study evaluated ibezapolstat, vancomycin, and fidaxomicin against C. difficile and Enterococcus in standalone and co-culture environments, finding that Enterococcus creates a protective microenvironment that impairs C. difficile treatment.

Why it matters — ACXP watchers would care because the data highlights ibezapolstat's potential advantage against C. difficile in complex infection environments, a key area for the company's lead candidate.

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

PRNewsWire · 17 Aug 2026positive

Acurx Pharmaceuticals announced that its proposed brand name, CIFBEZY, for its lead product candidate ibezapolstat received conditional acceptance from the FDA and federal trademark allowance from the USPTO. These initial milestones are intended to form the basis for the product's commercial identity as the company advances ibezapolstat toward its international Phase 3 registration program for both acute treatment and reduction of recurrence in C. difficile infection, with final FDA review of the name to be submitted at the time of the NDA marketing application.

Why it matters — The FDA conditional acceptance and USPTO trademark allowance represent early regulatory progress on the commercial identity of Acurx's lead candidate, ibezapolstat, as it moves toward its Phase 3 program for C. difficile infection.

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Acurx Pharmaceuticals, Inc. (ACXP) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The item announces the availability of the company's second-quarter earnings call transcript.

Why it matters — ACXP watchers would care because the earnings call transcript offers management's official discussion of the company's quarterly results and operations.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

PRNewsWire · 14 Aug 2026neutral

Acurx Pharmaceuticals reported its financial and operational results for the quarter ended June 30, 2026, and provided a business update. The announcement covers the late-stage biopharmaceutical company's development of a new class of antibiotics for difficult-to-treat bacterial infections.

Why it matters — ACXP watchers would care as the quarterly results and business update give an official view of the company's financial position and progress on its antibiotic pipeline.

FAQ

Frequently asked questions about ACXP stock

What is the ACXP stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Acurx Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACXP stock a buy right now?

Of the 3 analysts covering Acurx Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acurx Pharmaceuticals, Inc. 22 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACXP?

As at 8 Oct 2026, Acurx Pharmaceuticals, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will ACXP stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +700.0% from the last close, and Ticker Nerd's factor model ranks Acurx Pharmaceuticals, Inc. 22 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACXP stock forecast for 2030?

No analyst covering Acurx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.

How has ACXP stock performed over the past year?

Acurx Pharmaceuticals, Inc. returned -84.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acurx Pharmaceuticals, Inc. do?

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections.

What is the latest news on ACXP?

The most recent item we track (PRNewsWire, 29 Sept 2026): "Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection". Acurx Pharmaceuticals announced that the first patient has been enrolled in PATHFINDER, a Phase 2 clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection. Results from the trial, along with the planned ASPIRE Phase 3 study in acute CDI, may inform a future active-controlled Phase 3 registration trial in rCDI.

Company

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile. The company is also advancing ACX-375C, an antibiotic program intended to address resistant bacteria including MRSA, VRE, and drug-resistant Streptococcus pneumoniae. In addition to its lead and pipeline candidates, Acurx Pharmaceuticals Inc. works on anti-infective therapies for pathogens identified as priority threats by major public health agencies. The company operates in the biopharmaceutical sector, where its research is centered on unmet medical needs in infectious disease treatment and the development of new options for antibiotic-resistant infections.

CEO Mr. David P. Luci C.P.A., Esq., J.D. · 4 employees · United States · https://www.acurxpharma.com